Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$47.81 USD

47.81
9,409,499

-0.04 (-0.08%)

Updated Aug 14, 2025 04:00 PM ET

Pre-Market: $48.00 +0.19 (0.40%) 8:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

by Zacks Equity Research

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Zacks Equity Research

Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More

by Zacks Equity Research

Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

by Zacks Equity Research

Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Sheraz Mian headshot

Top Research Reports for Bank of America, Broadcom & Lowe's

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Broadcom (AVGO) and Lowe's Companies (LOW).

Zacks Equity Research

Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS

by Zacks Equity Research

Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.

Zacks Equity Research

Veeva Systems (VEEV) Boosts Portfolio of Cloud-Based Offerings

by Zacks Equity Research

Veeva Systems (VEEV) continues to boost its cloud-based offerings profile with the adoption of Vault PromoMats by Bristol Myers.

Zacks Equity Research

Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

by Zacks Equity Research

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

Zacks Equity Research

Should Value Investors Now Choose Bristol Myers (BMY) Stock?

by Zacks Equity Research

Let's see if Bristol Myers Squibb Company (BMY) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal

by Zacks Equity Research

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Zacks Equity Research

ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Zacks Equity Research

Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat

by Zacks Equity Research

Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.

Zacks Equity Research

Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

by Zacks Equity Research

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

Zacks Equity Research

Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.

Zacks Equity Research

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Zacks Equity Research

Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.

Zacks Equity Research

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

Zacks Equity Research

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 9.40% and 1.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View

by Zacks Equity Research

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.

Zacks Equity Research

Why Earnings Season Could Be Great for Bristol-Myers Squibb (BMY)

by Zacks Equity Research

Bristol-Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More

by Kinjel Shah

Let us take a look at four big drug/biotech companies, REGN, BMY, INCY & ZTS, which are gearing up for their earnings release.

Zacks Equity Research

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day

by Zacks Equity Research

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day